Akebia Therapeutics vs Puma Biotechnology
Akebia Therapeutics reported revenue of $236 million in fiscal 2025, about the same as Puma Biotechnology's $228 million in fiscal 2025. Akebia Therapeutics' revenue grew 47.5% in its latest year, and Puma Biotechnology's fell 0.9%. Akebia Therapeutics had an operating margin of 9.9%, against 16.3% at Puma Biotechnology. Free cash flow was $68 million at Akebia Therapeutics and $42 million at Puma Biotechnology.
Side by side
| Akebia Therapeutics | Puma Biotechnology | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $236M | $228M |
| Revenue growth | 47.5% | −0.9% |
| Revenue growth a year, last 5 years | −4.3% | 0.3% |
| Gross margin | 83.3% | 74.5% |
| Operating margin | 9.9% | 16.3% |
| Net margin | −2.3% | 13.6% |
| Free cash flow | $68M | $42M |
| Free cash flow margin | 28.7% | 18.3% |
| Return on capital | — | 48.2% |
| Net debt to EBITDA | −5.5x | −1.4x |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 21.9% | 3.2% |
| Last close | $0.42 | $7.12 |
| P/E at the last close | — | 15.5× |
| Insider trades, last 12 months | bought $86,588, sold $962,955 | sold $2.0 million |
| Piotroski F-score | 7 of 9 | 8 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Akebia TherapeuticsPuma Biotechnology
Operating margin
Percent of revenue
Akebia TherapeuticsPuma Biotechnology
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Akebia TherapeuticsPuma Biotechnology
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Akebia Therapeutics and Puma Biotechnology pages.